News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
|Title||Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S, Ratliff T, Liu X|
|Date Published||2013 Sep|
The androgen receptor (AR) signaling continues to be essential in castrate-resistant prostate cancer (CRPC). Taxel-based chemotherapy is the current standard treatment for CRPC patients. Unfortunately, almost all patients eventually develop resistance toward this chemotherapy. Significantly, it was recently found that the anti-tumor effect of paclitaxel in CRPC is due to its inhibition of AR activity via its inhibition of microtubule dynamics. Polo-like kinase 1 (Plk1), a critical regulator in many cell cycle events, is elevated in prostate cancer (PCa) and linked to tumor grades. Of note, we have previously shown that Plk1 phosphorylates CLIP-170 and p150(Glued) , two important regulators of microtubule dynamics.